COOPER COMPANIES, INC. (COO)

The Cooper Companies, Inc. (Cooper), a Delaware corporation organized in 1980 and traded on the NYSE (COO), is a global medical device company operating through two business units: CooperVision and CooperSurgical. CooperVision develops, manufactures, and markets a broad portfolio of single-use, two-week, and monthly contact lenses using advanced materials such as silicone hydrogel Aquaform technology and PC Technology, addressing spherical, toric, multifocal, and myopia management needs; its MiSight 1 day lens is the first FDA-approved and NMPA-approved product for slowing myopia progression in children aged 8-12. CooperVision's major manufacturing and distribution facilities are located in Belgium, Costa Rica, Hungary, Puerto Rico, the UK, and the U.S., and its key brands include Biofinity, clariti, MyDay, Proclear, and Avaira Vitality, competing primarily with Johnson & Johnson Vision Care, Alcon, and Bausch Health.

CooperSurgical, established in 1990, offers a diversified portfolio of medical devices and services focused on women's health, fertility, and family health, including IVF and cryopreservation products, office and surgical gynecology/obstetrics devices, contraception (notably PARAGARD, the only FDA-approved non-hormonal IUD), and cord blood/tissue storage services, with major facilities in Costa Rica, the Netherlands, the UK, and the U.S. CooperSurgical has grown through acquisitions, including Generate Life Sciences in fiscal 2022 and a pending acquisition of Cook Medical's Reproductive Health business for $875 million, and competes with companies such as Johnson & Johnson, Medtronic, Hologic, Vitrolife, and others across its various segments. Both business units operate in highly competitive, regulated markets, with products subject to extensive FDA oversight through 510(k) clearance or PMA approval pathways, and both compete on product quality, technological innovation, price, and customer service. The company employs approximately 300 people in research and development, focusing on new lens designs, manufacturing technologies, and expanding its fertility and OB/GYN product offerings, while market trends such as rising infertility rates, increasing women's healthcare needs, and growth in myopia management present ongoing growth opportunities for both segments.